The Valley Desk

NCT06317662 · Interventional trial

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Overall registry status Recruiting

Phase 2

Conditions Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov